Compare Amylx Pharmaceuticals Inc (AMLX) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs D R Horton Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.09 (market cap $1.98B), while D R Horton Inc trades at $152.26 (market cap $42.98B). The key difference: D R Horton Inc is far larger — about 21.7× Amylx Pharmaceuticals Inc's market cap, and D R Horton Inc pays a 1.19% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DHI | |
|---|---|---|
Market Cap | $1.98B | $42.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $184.04 |
52-Week Low | $7.64 | $129.82 |
Enterprise Value | $1.70B | $47.70B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
D.R. Horton (DHI) trades at $151.58, up 1.36% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with declining revenue ($34.25B in 2025) and net income margins (9.51%), though valuation metrics remain reasonable (P/E 14.23). Analyst consensus leans neutral with a $163.13 price target, while cash flow trends show volatility with a $1.51B net outflow in 2025.
The housing market headwinds and cyclical nature of homebuilding present near-term risks, but DHI's scale and operational efficiency offer stability. With the stock trading below consensus targets and showing technical support at $145, value-oriented investors may find opportunity amid sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
